10/100 · Low Risk
Manufactured by AAA Pharmaceutical, Inc.
No Serious Adverse Events Reported for Naja Naja Venom
1 FDA adverse event reports analyzed
Last updated: 2026-05-12
NAJA NAJA VENOM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AAA Pharmaceutical, Inc.. Based on analysis of 1 FDA adverse event reports, NAJA NAJA VENOM has a safety score of 10 out of 100. This lower score reflects a significant number of adverse event reports, suggesting that patients should discuss potential risks carefully with their healthcare provider. The most commonly reported adverse reactions for NAJA NAJA VENOM include DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NAJA NAJA VENOM.
Naja Naja Venom has a safety concern score of 10 out of 100, placing it in the low concern category based on analysis of FDA adverse event data. The FDA has received approximately 1 adverse event reports for this medication, which is primarily manufactured by Aaa Pharmaceutical, Inc..
The most commonly reported adverse events include Drug Ineffective. Of classified reports, 0.0% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Only one report of drug ineffectiveness was recorded.
The report is from a single male patient aged 67. There are no serious adverse events reported.
Patients taking Naja Naja Venom should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Naja Naja Venom received a safety concern score of 10/100 (low concern). This is based on a 0.0% serious event ratio across 1 classified reports. The score accounts for 1 total adverse event reports and 1 distinct reaction types. This relatively low score suggests a favorable safety profile in reported data.
Adverse event reports by sex: Male: 1. The most frequently reported age groups are age 67 (1 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 1 classified reports for NAJA NAJA VENOM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
If you are taking Naja Naja Venom, here are important things to know. The most commonly reported side effects include drug ineffective. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Given the single report, it is important to follow the prescribed dosage and consult a healthcare provider if the drug does not seem to be effective. More data is needed to fully understand the safety and efficacy profile of Naja Naja Venom. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA has received approximately 1 adverse event reports associated with Naja Naja Venom. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Naja Naja Venom include Drug Ineffective. By volume, the top reported reactions are: Drug Ineffective (1 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Naja Naja Venom.
Out of 1 classified reports, N/A (0.0%) were classified as serious and 1 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Naja Naja Venom break down by patient sex as follows: Male: 1. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Naja Naja Venom adverse events are: age 67: 1 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Naja Naja Venom adverse event reports is Aaa Pharmaceutical, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
You can report adverse events from Naja Naja Venom to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Naja Naja Venom has a safety concern score of 10 out of 100 (low concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Only one report of drug ineffectiveness was recorded.
Key safety signals identified in Naja Naja Venom's adverse event data include: Single report of ineffectiveness.. Limited data available.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Given the single report, it is important to follow the prescribed dosage and consult a healthcare provider if the drug does not seem to be effective. More data is needed to fully understand the safety and efficacy profile of Naja Naja Venom.
Naja Naja Venom has 1 adverse event reports on file with the FDA. The report is from a single male patient aged 67. The volume of reports for Naja Naja Venom reflects both the drug's usage level and the vigilance of the reporting community.
Explore other medications manufactured by AAA Pharmaceutical, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with NAJA NAJA VENOM:
Drugs related to NAJA NAJA VENOM based on therapeutic use, drug class, or shared indications: